 Grants Awarded.
The Center for Health Behavior Research builds upon our previous success in West Virginia. Click on the links below for a list
of clinical trials by time period.
2006 - Present
2006 – Nabi Biopharmaceuticals, “Phase 2, Multi-Center, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm, Study to Assess Efficacy and Safety of 3’-aminomethylnicotine-P. aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX™) as an Aid to Smoking Cessation”
2006 – Pharmacia and Upjohn Company LLC, “A Phase 3, Multi-Center, Randomized, Head-to-Head Comparative Efficacy Study of Nicotine Hydrogen Tartrate Gum (4mg) and Nicotine Polacrilex Gum (4mg) on the Speed to Subjectivity Meaningful Relief of Acute Craving.”
2006 - Sanofi Aventis, “An International, Seven-Week, Double-Blind, Placebo-Controlled Two Parallel Group Study to Assess the Efficacy of SSR591813L 40 mg Bid as an Aid to Smoking Cessation in Cigarette Smokers.”
2006- National Institute of Drug Abuse/NIH, "Phase 2, Double-Blind, Placebo-Controlled Trial of Selegiline as an Aid to Smoking Cessation."
2006 Pinney Associates and Concentrics, "Study to Assess the Efficacy of 4mg Nicotine Lozenge vs. Varenicline in Relief of Provoked Craving."
2006- National Institute of Drug Abuse/NIH, "Physiologic Impact of Variation in Smoke pH." 1 R01 DA019691-01. PI: Pamela I. Clark.
2008- University of Maryland School of Public Health Seed Money Grant Program. "Physiologic impact of variation in pH of new smokeless, spitless tobacco products." PI: Jessica M. Rath.
2008- Nabi Biopharmaceuticals, “Phase 3, NicVAX™ as an Aid to Smoking Cessation.”
2001 - 2005
2000- National Cancer Institute/NIH, "Business Practices and Minor’s Access to Tobacco." 5RO1CA086232-04.
2001 - Parke-Davis, "A 6-week, Double-Blind, Randomized, Multicenter, Flexible-Dose, Placebo-Controlled Study of Pagoclone in Patients with Generalized Anxiety Disorder."
2001 - Takeda Pharmaceuticals America, Inc., "A Randomized Comparator, Controlled, Double-Blind Study of the Liver Safety of Pioglitazone HCI Versus Glyburide with Metformin and Insulin as Part of Step Therapy in Subjects with Type 2 (Non-Insulin Dependent) Diabetes."
2001 - Bayer Corporation, "A Randomized, Multicenter, Open-Label Pilot Study to Assess the Comparative Onset of Efficacy of CR Nicotine® Gum to Nicorette in Relieving Acute Craving Following Exposure to Smoking Cue-Induced Craving in Adult Volunteer Cigarette Smokers Who Smoke 10 to 24 Cigarettes Per Day."
2001 - DrugAbuse Sciences, "An Open Label Safety Study of Naltrexone Depot in Treatment of Alcohol Dependence."
2001 - Pfizer, "A 6-week, Double-Blind, Randomized, Multicenter, Fixed-Dose, Placebo-Controlled, Study of Pagoclone Dosed Once a Day in Patients with Generalized Anxiety Disorder."
2001 - Sanofi-Synthelabo Research, "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety of SR141716 in Obese Patients with Untreated Dyslipidemias."
2002 - National Institutes of Health (NIH-1R01 CA90884-01A1), "Efficacy of Bupropion for Treating Spit Tobacco Users."
2002 - Sanofi-Synthelabo, "Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5mg/day or 20mg/day, versus Placebo, as an Aid to Smoking Cessation - A Single Country, Randomized, Double-blind, 3-Arm, Placebo-controlled, Parallel-group, Fixed Dose, 52-week Multicenter, Phase III trial; 2-week Screen, 10-week Treatment, 40-week Follow-up."
2002 - Genaissance, "A Case Control Investigation Exploring the Relationship between Gene Variants (HAP™ Markers) and Agranulocytosis or Granulocytopenia in Adult Patients Treated with Clozapine."
2002 - Eli Lilly & Company, "Randomized, Double-Blind, Placebo-Controlled Study of Atomozetine HCL in Children & Adolescents with ADHD and Comorbid Anxiety Disorder."
2003 - Pfizer, "Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study with Follow-Up Evaluating the Safety & Efficacy of Varenicline Tartrate (CP-526,555) in Comparison to Zyban for Smoking Cessation."
2003 - Sanofi-Synthelabo, "Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 4 mg/day or 20 mb/day Versus Placebo as an Aid to Prevention of Relapse to Smoking - a Multiple Country (Worldwide), Randomized, Double-Blind, 3-arm, Placebo-Controlled, Parallel-Group, Fixed Dose, 2-Year, Multicenter, Phase III Trial; 1-Year Active Treatment, 1-year-Followup."
2003 - Year 2, National Institutes of Health (NIH-IR01 CA90884-01A1). "Efficacy of Bupropion for Treating Spit Tobacco Users." (Collaboration with Mayo Clinic)
2003 - Sanofi-Synthelabo, "A Double-blind, Multicenter Study Evaluating the Efficacy and Safety of One Fixed Dose of SR58611A (700 mg/day) Versus Placebo and Paroxetine (20 mg/day) in Patients with a Recurrent Major Depressed Episode."
2003 - Sanofi-Synthelabo, "A Dose-Ranging Placebo-Controlled Study of SL64.0155-10 at the Doses of 0.5 mg, 2 mg, and 8 mg for 12 Weeks in Patients with Mild-to-Moderate Alzheimer’s Disease."
2004 - AstraZeneca, "A Multicenter, Randomized, Parallel-group, Double-blind, Phase III Comparison of the Efficacy & Safety of Quetiapine Fumerate (oral tablets 400 mg to 800 mg daily in divided doses) to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Divalproex) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients."
2004 - Sanofi-Synthelabo, "Comparison of the Efficacy & Safety of 3 Oral Doses of SSR591813, 20 mg, 40 mg, 80 mg Twice Daily, Versus Placebo as an Aid to Smoking Cessation. A US, Multicenter, Randomized, Double-blind, 4-arm, Fixed Dose, 7-week Treatment, Phase II Trial."
2004 - Campbell University, "Evaluation of 24 Hours Motor Activity of Bupropion XL vs Placebo in Patients with Major Depressive Disorder."
2004 – Year 3, National Institutes of Health (NIH-1RO1 CA90884-01A1). "Efficacy Bupropion for Treating Spit Tobacco Users." (Collaboration with Mayo Clinic).
2004 - Sanofi-Synthelabo, "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study to Assess Efficacy & Safety of Rimonabant 20 mg versus Placebo on Weight Loss & Frequency of Binge Episodes in Obese Patients with Food Craving."
2004 - GlaxoSmithKline, "Cortical Myelin Preservation in Schizophrenic Patients." Investigator Initiated Project.
2004 - Bristol Myers Squibb, "A Multicenter, Long-Term, Open-Label Study to Assess the Safety and Tolerability of Aripirazole as Adjunctive Therapy in the Treatment of Outpatients with Major Depressive Disorder."
2004 - Pfizer, "A Randomized, Double-Blind, Parallel-Group Study Comparing the Efficacy of CP-601,932 and CP-601,927 Versus Placebo in Promoting Smoking Cessation in Health Smokers, with Zyban Active Control."
2005 - GlaxoSmithKline, “Cortical Myelin Preservation in Schizophrenic Patients .” Investigator Initiated Project.
2005 - Bristol Myers Squibb, “A Multicenter, Long-Term, Open-Label Study to Assess the Safety and Tolerability of Aripirazole as Adjunctive Therapy in the Treatment of Outpatients with Major Depressive Disorder.”
2005 - Sanofi-Aventis, “An Eight- Week, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety and Tolerability of One Fixed 100 mg Dose of Saredutant in Patient s with Major Depressive Disorder.”
2005 - National Institute of Drug Abuse, “Applalachian TriState Node of Clinical Trials Network Research Project . 5-Year Study.”
2001 - Present
2001 - Parke-Davis, "A 6-week, Double-Blind, Randomized, Multicenter, Flexible-Dose, Placebo-Controlled Study of Pagoclone
in Patients with Generalized Anxiety Disorder."
2001 - Takeda Pharmaceuticals America, Inc., "A Randomized Comparator, Controlled, Double-Blind Study of the Liver Safety
of Pioglitazone HCI Versus Glyburide with Metformin and Insulin as Part of Step Therapy in Subjects with Type 2 (Non-Insulin
Dependent) Diabetes."
2001 - Bayer Corporation, "A Randomized, Multicenter, Open-Label Pilot Study to Assess the Comparative Onset of Efficacy
of CR Nicotine® Gum to Nicorette in Relieving Acute Craving Following Exposure to Smoking Cue-Induced Craving in Adult
Volunteer Cigarette Smokers Who Smoke 10 to 24 Cigarettes Per Day."
2001 - DrugAbuse Sciences, "An Open Label Safety Study of Naltrexone Depot in Treatment of Alcohol Dependence."
2001 - Pfizer, "A 6-week, Double-Blind, Randomized, Multicenter, Fixed-Dose, Placebo-Controlled, Study of Pagoclone Dosed
Once a Day in Patients with Generalized Anxiety Disorder."
2001 - Sanofi-Synthelabo Research, "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter
Study of Weight-Reducing Effect and Safety of SR141716 in Obese Patients with Untreated Dyslipidemias."
2002 - National Institutes of Health (NIH-1R01 CA90884-01A1), "Efficacy of Bupropion for Treating Spit Tobacco Users."
2002 - Sanofi-Synthelabo, "Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5mg/day or 20mg/day, versus
Placebo, as an Aid to Smoking Cessation - A Single Country, Randomized, Double-blind, 3-Arm, Placebo-controlled, Parallel-group,
Fixed Dose, 52-week Multicenter, Phase III trial; 2-week Screen, 10-week Treatment, 40-week Follow-up."
2002 - Genaissance, "A Case Control Investigation Exploring the Relationship between Gene Variants (HAP™ Markers)
and Agranulocytosis or Granulocytopenia in Adult Patients Treated with Clozapine."
2002 - Eli Lilly & Company, "Randomized, Double-Blind, Placebo-Controlled Study of Atomozetine HCL in Children & Adolescents
with ADHD and Comorbid Anxiety Disorder."
2003 - Pfizer, "Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study with Follow-Up Evaluating
the Safety & Efficacy of Varenicline Tartrate (CP-526,555) in Comparison to Zyban for Smoking Cessation."
2003 - Sanofi-Synthelabo, "Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 4 mg/day or 20 mb/day
Versus Placebo as an Aid to Prevention of Relapse to Smoking - a Multiple Country (Worldwide), Randomized, Double-Blind, 3-arm,
Placebo-Controlled, Parallel-Group, Fixed Dose, 2-Year, Multicenter, Phase III Trial; 1-Year Active Treatment, 1-year-Followup."
2003 - Year 2, National Institutes of Health (NIH-IR01 CA90884-01A1). "Efficacy of Bupropion for Treating Spit Tobacco
Users." (Collaboration with Mayo Clinic)
2003 - Sanofi-Synthelabo, "A Double-blind, Multicenter Study Evaluating the Efficacy and Safety of One Fixed Dose of SR58611A
(700 mg/day) Versus Placebo and Paroxetine (20 mg/day) in Patients with a Recurrent Major Depressed Episode."
2003 - Sanofi-Synthelabo, "A Dose-Ranging Placebo-Controlled Study of SL64.0155-10 at the Doses of 0.5 mg, 2 mg, and
8 mg for 12 Weeks in Patients with Mild-to-Moderate Alzheimer’s Disease."
2004 - AstraZeneca, "A Multicenter, Randomized, Parallel-group, Double-blind, Phase III Comparison of the Efficacy & Safety
of Quetiapine Fumerate (oral tablets 400 mg to 800 mg daily in divided doses) to Placebo When Used as Adjunct to Mood Stabilizers
(Lithium or Divalproex) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients."
2004 - Sanofi-Synthelabo, "Comparison of the Efficacy & Safety of 3 Oral Doses of SSR591813, 20 mg, 40 mg, 80 mg
Twice Daily, Versus Placebo as an Aid to Smoking Cessation. A US, Multicenter, Randomized, Double-blind, 4-arm, Fixed Dose,
7-week Treatment, Phase II Trial."
2004 - Campbell University, "Evaluation of 24 Hours Motor Activity of Bupropion XL vs Placebo in Patients with Major
Depressive Disorder."
2004 – Year 3, National Institutes of Health (NIH-1RO1 CA90884-01A1). "Efficacy Bupropion for Treating Spit Tobacco
Users." (Collaboration with Mayo Clinic).
2004 - Sanofi-Synthelabo, "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study
to Assess Efficacy & Safety of Rimonabant 20 mg versus Placebo on Weight Loss & Frequency of Binge Episodes in Obese
Patients with Food Craving."
2004 - GlaxoSmithKline, "Cortical Myelin Preservation in Schizophrenic Patients." Investigator Initiated Project.
2004 - Bristol Myers Squibb, "A Multicenter, Long-Term, Open-Label Study to Assess the Safety and Tolerability of Aripirazole
as Adjunctive Therapy in the Treatment of Outpatients with Major Depressive Disorder."
2004 - Pfizer, "A Randomized, Double-Blind, Parallel-Group Study Comparing the Efficacy of CP-601,932 and CP-601,927 Versus
Placebo in Promoting Smoking Cessation in Health Smokers, with Zyban Active Control."
2005 - GlaxoSmithKline, “Cortical Myelin Preservation in Schizophrenic Patients .” Investigator Initiated Project.
2005 - Bristol Myers Squibb, “A Multicenter, Long-Term, Open-Label Study to Assess the Safety and Tolerability of Aripirazole as Adjunctive Therapy in the Treatment of Outpatients with Major Depressive Disorder.”
2005 - Sanofi-Aventis, “An Eight- Week, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety and Tolerability of One Fixed 100 mg Dose of Saredutant in Patient s with Major Depressive Disorder.”
2005 - National Institute of Drug Abuse, “Applalachian TriState Node of Clinical Trials Network Research Project . 5-Year Study.”
1996 -2000
1997 - SANO Corporation, "The Evaluation of the Efficacy and Safety of a Transdermal Delivery System of Nicotine/Mecamylamine
in Cigarette Smokers."
1997 - DynaGen, Inc., "The Determination of the Sensitivity of the NicCheck I Test in Identifying the Use of Smokeless
Tobacco."
1997 - SANO Corporation, "The Evaluation of Continuous Abstinence at Three, Six, and Twelve Months After the Quit Date
in Nicotine/Mecamylamine Transdermal Studies."
1997 - SANO Corporation, "The Evaluation of the Efficacy and Safety of a Transdermal Delivery System of Nicotine/Mecamylamine
in Cigarette Smokers with a History of Hypertension who are Maintained on Antihypertensive Pharmacotherapy."
1997 - SANO Corporation, "The Evaluation of the Safety of a Transdermal Delivery System of Nicotine/Mecamylamine in Cigarette
Smokers in Patients with Gastrointestinal Disorders."
1998 - Glaxo Wellcome, "A Multi-Center Evaluation of the Effects of Zyban™ (bupropion hydrochloride sustained release
tablets) versus Placebo in a Population of Smokers with COPD."
1998 - Glaxo Wellcome, "A Double-Blind Placebo-Controlled Clinical & Safety Evaluation of Zyban™ for Smokeless
Tobacco Cessation."
1998 - Glaxo Wellcome, "A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group, Dose
Response Evaluation of 1555U88 (2.5mg/day, 5mg/day, 10mg/day, 15mg/day) and Zyban™ (bupropion hydrochloride) Sustained
Release (300mg/day) versus Placebo As Aids to Smoking Cessation."
1998 - SmithKline Beecham Consumer Healthcare, "A Randomized, Double-Blind, Parallel Group Study to Measure the Efficacy & Safety
of Nicotine Gum (2mg & 4mg) for Smoking Cessation by Gradual Reduction."
1999 - Knoll Pharmaceutical Company, "A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study
to Examine the Efficacy & Safety of Meridia (sibutramine hydrochloride) Plus Adjunctive Nicotine Therapy (Habitrol Patch)
as an Aid for Smoking Cessation in Patients who Smoke Cigarettes."
1999 - Bristol-Myers Squibb, "A Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Buspirone
as an Aid to Smoking Cessation."
1999 - Pharmacia & Upjohn, "A Double-Blind, Randomized, Placebo-Controlled Multi-Center Trial of a Nicotine Inhaler
in Smoking Reduction: A 15-month Trial."
1999 - Synthelabo Research Inc., "Comparison of the Efficacy & Safety of 3 Oral Doses of Befloxatone 2.5 mg/day, 5
mg/day & 10 mg/day Versus Placebo as an Aid to Smoking Cessation in Smokers: A Randomized, Double-Blind, 6-Month Multi-Center
Phase II Trial 10-Week Active Treatment - 3.5-Month Follow-Up."
1999 - Glaxo Wellcome, "A Multi-Center, Randomized, Parallel, Placebo-Controlled, One-Year Study of the Efficacy and Safety
of Zyban™ (Bupropion Hydrochloride Sustained Release Tablets) versus Placebo as Aids to Smoking Cessation Treatment
in Adult Cigarette Smokers Previously Treated with Bupropion."
1999 - Glaxo Wellcome, "A Multi-Center, Double-Blind. Placebo-Controlled Comparison of the Safety & Efficacy & Effects
on Sexual Functioning of Wellbutrin (Bupropion HCI) Sustained Release (SR) & Fluoxetine in Outpatients with Moderate to
Severe Recurrent Major Depression."
2000 - Eli Lilly Corporation, "Open-Label Combination of Olanzapine plus Fluoxetine in Major Depressive Disorder."
2000 - Pfizer, Inc., "A Seven-Week, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study Evaluating the Safety
and Efficacy of Three Doses of CP-526,555 (0.3 mg QD, 1 mg QD, and 1 mg BID) in Comparison with Zyban™ SR in Smoking
Cessation."
2000 - Sanofi-Synthelabo Research, "A Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Safety and Efficacy
of SR141716 as an Aid to Smoking Cessation."
2000 - Parke-Davis Pharmaceuticals America, Inc., "A 6-Week, Double-Blind, Randomized, Multi-Center, Flexible-Dose, Placebo-Controlled
Study of Pagoclone in Patients With Generalized Anxiety Disorder."
Return to Top
1991 - 1995
1992 - Kabi Pharmacia, "A Pilot Study Assessing the Nicotine Nasal Spray (NNS) as a Pharmacological Adjunct for Smoking
Cessation and Prevention in Chronic Obstructive Pulmonary Disease (COPD) Patients."
1994 - Research Testing Laboratories & Ciba-Geigy Pharmaceuticals, "A Validation Study to Determine the Ability of
Cigarette Smokers with Six Specified Medical Conditions to Understand the Need to Consult a Physician Before Using the Habitrol
OTC Product."
1994 - Marion Merrell Dow, "4-Year Follow-up on the Pivotal Nicotine Transdermal Trial for Smoking Cessation."
1994 - Burroughs Wellcome, "A Multi-Center Dose Response Evaluation of Wellbutrin (Bupropion Hydrochloride) Sustained-Release
Versus Placebo as an Aid to Smoking Cessation."
1994 - DynaGen, Inc., "A Pilot Phase 3 Study of NicErase-SL for Smoking Cessation."
1995 - Ciba Self-Medication, Inc., "Double-Blind Evaluation of Waking Hour Usage of Habitrol vs. Pseudo Placebo in the
Treatment of Tobacco Withdrawal in Cigarette Smokers."
1995 - Pharmacia, "A Double-Blind Placebo-Controlled Evaluation of a Nicotine Sublingual Tablet in Smoking Cessation."
1995 - DynaGen, Inc., "A Multi-Center Pivotal Phase 3 Study of NicErase-SL for Smoking Cessation."
1989 - 1990
1989 - Marion Merrell Dow Pharmaceuticals "The Evaluation of the Safety & Efficacy of Nicorette 4mg as an Aid for
Cessation of Cigarette Smoking in Highly Dependent Smokers."
1989 - ALZA Corporation, "A Placebo-Controlled Study Assessing the Safety & Relative Efficacy of Two Dosing Regimens
of a New Transdermal Nicotine System."
1990 - Kabi Pharmacia, "Nicotine Inhaler (Nicohaler) Versus Placebo in Smoking Cessation: A Clinical Evaluation."
|
